Chelsea and Westminster Hospital
NHS Foundation Trust

Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group

Summary of Main Points from the Meeting held on Monday 10th July 2023

2. Minutes and Summary Notes from last meeting

This meeting was held via Teams. The Minutes and Summary notes of the Medicines Group Meeting held on 15th May 2023 were approved. The summary notes will be disseminated and published on the Trust intranet. A quarterly summary report will be drafted and forwarded to the Trust Patient Safety Group meeting for inclusion on the agenda in due course.

3. Matters Arising

The Group noted the matters arising from the previous meeting.

4. Business to be transacted by the Medicines Group

4.1 Formulary Applications

Full Applications

- **Nil**

Ex-Panel Applications

- **Tostran® Testosterone 2% Gel**

Requested by: GUM
Proposal: Add to the formulary in line with its licensed indication - Replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests.
Rational: Delivers half the testosterone dose as Testogel 16.2mg/g pump: Testogel 16.2mg/g gel pump delivers: 20mg in 1 pumps Tostran 2% gel pump delivers: 10mg in 1 pump This provides more flexibility with dosing where lower doses of testosterone are needed such as in cases of a supratherapeutic serum testosterone levels or haematological toxicity, whilst maintaining an accurate dosing mechanism with the pump formulation.
Outcome: Approved for addition to the Trust Formulary

- **Tolterodine 2mg SR Capsule**

Requested by: Urology
Proposal: Add to the formulary in line with its licensed indication - Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with Overactive Bladder Syndrome.
Rational: Tolterodine 4mg SR Capsules currently included on the formulary. Addition of 2mg capsules provides more flexibility with dosing.
Outcome: Approved for addition to the Trust Formulary

Removals

- **Nil**

NICE Approved drug applications

- TA877 Finerenone for treating chronic kidney disease in type 2 diabetes (23/03/2023) Proposal: Add to the formulary in line with NICE TA877

Outcome: Approved for addition to the Trust Formulary for use in line with NICE TA877

Pharmacoeconomic Board requests

- **Bevacizumab - Refractory upper GI bleeding**

Approved by the Pharmacoeconomic Board on 24/05/2023
Outcome: Noted

- **Infliximab for granulomatous disorder**

Approved by the Pharmacoeconomic Board on 30/05/2023
Outcome: Noted

- **Infliximab for TB IRIS**

Approved by the Pharmacoeconomic Board on 02/06/2023
Outcome: Noted

- **Infliximab for TB IRIS**

Approved by the Pharmacoeconomic Board on 06/06/2023
Outcome: Noted

- **Tocilizumab for TB IRIS**

Approved by the Pharmacoeconomic Board on 03/07/2023
Outcome: Noted

4.2 Trust Medicines Policy

- **TMP: Section 3 - Prescribing**

Update to the circumstances where a prescription may be issued to a patient at a hospital out-patient consultation in line with NWL prescribing guidance.

- **Adult IV Administration Guide**

- ***Terlipressin***

Recent updates have suggested that there are less side effects with terlipressin given as an infusion compared to bolus doses. It is unlicensed but is detailed in the Medusa Monograph and other Hepatology centres are administering via infusion.
Outcome: Approved

- ***Infliximab***

Additional administration method has been added to the existing Infliximab monograph: In adult patients on maintenance therapy who have tolerated at least 3 initial 2-hour infusions (induction phase) consideration may be given to administering subsequent infusions over 1 hour.
Outcome: Approved

- ***Ferric Derisomaltose (Previously Monofer)***

The trade name removed from this brand of Iron as it is now to be referred to by the INN 'Ferric Derisomaltose'
Outcome: Approved

4.3 Medicines Optimisation

- **Nil**

4.4 NICE Technical Appraisals and Guidance

a) NICE Technology Appraisals

TA appraisals published since previous TMG meeting: 20

- **TA886 Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy (10/05/2023)**

Formulary status / Action
Not included on the formulary
Action: Add to the formulary following receipt of an application form from the Oncology Department

- **TA887 Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (10/05/2023)**

Formulary status / Action
Not included on the formulary
Action: Add to the formulary following receipt of an application form from the Oncology Department

- **TA888 Risankizumab for previously treated moderately to severely active Crohn's disease (17/05/2023)**

Formulary status / Action
Included on the formulary for another indication
Numbers likely to treat at CWH site: 5-10 patients per year
Numbers likely to treat at WMUH site: 5-10 patients per year

- **TA889 Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (Terminated appraisal) (17/05/2023)**

Formulary status / Action
Action: Nil - Terminated Appraisal

- **TA890 Difelikefalin for treating pruritus in people having haemodialysis (17/05/2023)**

Formulary status / Action
Not included on the formulary
Action: Nil - Not applicable as condition not treated at CWFT

- **TA891 Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia (31/05/23)**

Formulary status / Action Included on the formulary for another indication
Numbers likely to treat at CWH site: 6 patients per year
Numbers likely to treat at WMUH site: 6 patients per year

- **TA892 Mosunetuzumab for treating relapsed or refractory follicular lymphoma (31/05/23)**

Formulary status / Action
Action: Nil - Not recommended

- **TA893 Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over (07/06/2023)**

Not applicable to CWFT - Condition not treated at CWH and WMUH site

TA894 Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma (07/06/2023)
Formulary status / Action
Action: Nil - Not recommended

- **TA895 Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy (07/06/2023)**

Not applicable to CWFT - Condition not treated at CWH and WMUH site

- **TA896 Bulevirtide for treating chronic Hepatitis D (07/06/2023)**

Formulary status / Action
Not included on the formulary
Action: Nil - Not applicable as CWFT not a commissioned site

- **TA897 Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (06/06/2023)**

Formulary status / Action Included on the formulary for this indication
Numbers likely to treat at CWH site: 6 patients per year
Numbers likely to treat at WMUH site: 6 patients per year

- **TA898 Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer (14/06/2023)**

Formulary status / Action Included on the formulary for another indication

Numbers likely to treat at CWH site: TBC
Numbers likely to treat at WMUH site: TB

TA899 Esketamine for treating major depressive disorder in adults at imminent risk of suicide (06/06/2023) Formulary status / Action
Action: Nil - Terminated Appraisal

- **TA900 Tixagevimab plus cilgavimab for preventing COVID-19 (14/06/2023)**

Formulary status / Action
Action: Nil - Not recommended

- **TA901 Cemiplimab for treating recurrent or metastatic cervical cancer (20/06/2023) Formulary status / Action**

Action: Nil - Terminated Appraisal

- **TA902 Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (21/06/2023)**

Formulary status / Action Included on the formulary for another indication
Numbers likely to treat at CWH site: TBC
Numbers likely to treat at WMUH site: 100 patients per year

- **TA903 Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer (21/06/2023)**

Formulary status / Action Included on the formulary for another indication
Numbers likely to treat at CWH site: 3 patients per year
Numbers likely to treat at WMUH site: 0 patients per year

- **TA904 Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer (21/06/2023**

Formulary status / Action Included on the formulary for another indication
Not applicable to CWFT - Condition not treated at CWH and WMUH site

- **TA905 Upadacitinib for previously treated moderately to severely active Crohn's disease (21/06/2023)**

Formulary status / Action
Included on the formulary for another indication
Numbers likely to treat at CWH site: 20 patients per year
Numbers likely to treat at WMUH site: 5-10 patients per year

b) NICE Highly Specialised Technology Appraisals

HST appraisal published since previous TMGG meeting: 2

- **HST25 Lumasiran for treating primary hyperoxaluria type 1 (19/04/2023)**

Action: Nil - Not applicable to CWFT

- **HST26 Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency (19/04/2023)**

Action: Nil - Not applicable to CWFT

4.5 IVIG requests

- **IVIG Issues for April 2023 - CW Site**

There were 11 IVIG issues in December 2022, with 4 new requests
Outcome: Noted

- **IVIG Issues for April 2023 - WMUH Site**

There were 8 IVIG issues in March 2023, with 5 new requests
Outcome: Noted

- **IVIG issues for May 2023 - CWH Site**

here were 16 IVIG issues in May 2023 with 7 new requests
Outcome: Noted

- **IVIG issues for May 2023 - WMH Site**

There were 8 IVIG issues in March 2023, with 2 new requests
Outcome: Noted

4.6 Items for noting

- **Quarterly Controlled Drug Summary Report - Q4 2022/23**

Quarterly Controlled Drug Summary Report for Q3 2022/23
Outcome: Noted

- **Quarterly Controlled Drugs Accountable Officer Report - Q4 2022/23**

Quarterly CD Accountable Officer Report for Q3 2022/23
Outcome: Noted

- **Medication Safety Bulletin: Intravenous Iron**

Medication Safety Bulletin relating to Intravenous Iron
Outcome: Noted

- **Medication Safety Bulletin: Intravenous Iron preparations**

Medication Safety Bulletin: Reporting Intravenous iron Preparations
Outcome: Noted

- **MHRA Drug Safety Update - April 2023**

MHRA update for April 2023
Outcome: Noted

- **Trust response to MHRA Risk Alerts relating to antimicrobials:**

Nitrofurantoin - Pulmonary and Hepatic Toxicity
Aminoglycoside - Ototoxicity
Outcome: Plan agreed and actions noted

- **MHRA Drug Safety Update - May 2023**

MHRA update for May 2023
Outcome: Noted

- **MHRA Drug Safety Update - June 2023**

MHRA update for June 2023
Outcome: Noted

4.7 Meeting minutes for noting

- **Medication Safety Group meeting minutes - May 2023**

Minutes from Medical Safety Group meeting held May 2023
Outcome: Noted

- **Antimicrobial Stewardship Group meeting minutes - May 2023**

Minutes from Antimicrobial Stewardship Group meeting held May 2023
Outcome: Noted

5. Any other business

Nil

6. Date of next meeting

Next meeting
Date 25th September 2023
Time: 8am-9am
Location: via Teams